Delivering Improved Cardiac Safety Liabilities for Therapeutic Drugs Using the Contractome-AI

作为InoCardia有限公司的创始人，我运用了30年与制药行业保持一致的经验，于2013年将心脏Work-Loop收缩能力平台商业化，作为考文垂大学的一家衍生公司。我的学术研究商业化始于一个愿景，即制药行业内部存在着开发改进的生理相关模型来评估心脏收缩能力的基本需求。这些讨论为学术研究项目奠定了基础，导致了基于组织/细胞的新型工作循环平台的开发，该平台开辟了更安全的药物开发的新途径。Work-Loop平台通过成立衍生公司InoCardia Ltd实现商业化，专注于提供心脏药物安全评估服务。客户包括全球制药公司和药物发现生物技术公司。该公司已从外部融资机构(即InnovateUK)和风险资本家那里获得了英国和欧盟的投资资金。该公司目前提供世界上第一个非临床收缩能力测试，提供卓越的预测性，目前正在给心脏安全评估领域带来革命性的变化。除了获得外部资金、保护知识产权、获得利益相关者的支持、学习商业语言、了解市场需求和动态之外，还有很多东西需要学习，才能将学术研究想法转化为强大的商业产品。不仅是我的两个孩子，而且是中小学生和大学学生的榜样，这一概念对我来说极其重要。我真的相信“世界应该是你的牡蛎”。我热衷于商业/研究启发的教学，目前在BSC/MSC课程中教授“如何组建一家衍生公司”。我认为这个奖项是一个机会，使我能够激励女性科学家走向商业创新。虽然我是InoCardia的创始人和现任CSO，但我在3年前辞去了InoCardia首席执行官一职，因为我觉得自己没有信心或足够的商业经验来担任公司的首席执行官。我认为，创新女性奖是一条重要的支持性途径，可以帮助你获得必要的技能，从而在未来成为首席执行官。我认为，通过这个奖项获得的支持不仅会让我对自己作为领导者和技术创新者的能力更有信心，还有助于提高公司的形象。这将使我能够在制药行业内宣传InoCardia的愿景，并为我提供一个商业支持网络、网络活动和吸引更多投资的机会。

As the founder of InoCardia Ltd, I have applied 30 years' experience aligned to the pharmaceutical industry to commercialise the cardiac Work-Loop contractility platform as a spin-out company from Coventry University in 2013\.The commercialisation of my academic research started with a vision that there was a fundamental need within the Pharmaceutical Industry for the development of improved physiological relevant model to assess cardiac contractility. These discussions underpinned academic research projects leading to the development of the novel tissue/cell-based Work-Loop Platform that opened-up new pathways to safer drug development. The Work-Loop Platform was commercialised through the formation of the spin-out company InoCardia Ltd, focussing on providing a cardiac drug safety assessment service. Customers have included global pharmaceutical companies and drug discovery biotechs. The company has generated UK & EU investment funding from external funding bodies (i.e InnovateUK) and venture capitalists. The company currently offers the world's first nonclinical contractility assay which offers superior predictivity and is currently revolutionising the field of cardiac safety assessment. There is a lot to learn to translate an academic research idea into a robust commercial offering, in addition to accessing external funding, protecting intellectual property, getting buy-in from stakeholders, learning the language of business and understanding market requirements and dynamics.The notion of being a role model not only to my two children but also students in Schools and at University is extremely important to me. I truly believe that the "world should be your oyster". I am passionate about Business/Research inspired teaching and currently teach "How to form a spin out company", on BSc/MSc programmes. I see this award as an opportunity to enable me to inspire female scientists towards business innovation. Although I am the founder and current CSO for InoCardia, I stepped down from being InoCardia's CEO 3 years ago as I didn't feel that I had the confidence or adequate business experience to be CEO for my company. I see the Women in Innovation award an important supportive route to gain necessary skills to progress to CEO in the future. I think support via this award will not only help give me more confidence in my abilities as a leader and tech innovator but also helped raise the company's profile. It will enable me to promote InoCardia's vision within the Pharmaceutical Industry and provide me with the access to a network of business support, networking events and attract further investment.